Selected research
Industry Research
Melanocortin Receptor 4 Industry Research Report 2026
Market perspective
The global Melanocortin Receptor 4 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Melanocortin Receptor 4 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Melanocortin Receptor 4 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Melanocortin Receptor 4 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Melanocortin Receptor 4 include Pfizer Inc., AstraZeneca Plc, Rhythm Pharmaceuticals, Inc., Retrophin Inc., Palatin Technologies, Inc., Obexia AG and Mallinckrodt Plc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Melanocortin Receptor 4 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Melanocortin Receptor 4.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Melanocortin Receptor 4 Market by Company
Pfizer Inc.
AstraZeneca Plc
Rhythm Pharmaceuticals, Inc.
Retrophin Inc.
Palatin Technologies, Inc.
Obexia AG
Mallinckrodt Plc
Melanocortin Receptor 4 Segment by Type
Cosyntropin
Corticotropin
Bremelanotide
Others
Melanocortin Receptor 4 Segment by Application
Genito Urinary System
Infection Disease
Women's Health
Metabolic Disorder
Others
Melanocortin Receptor 4 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Melanocortin Receptor 4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Melanocortin Receptor 4 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Melanocortin Receptor 4.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Melanocortin Receptor 4 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cosyntropin
- Corticotropin
- Bremelanotide
- Others
Applications
- Genito Urinary System
- Infection Disease
- Women's Health
- Metabolic Disorder
- Others
Companies covered
- Pfizer Inc.
- AstraZeneca Plc
- Rhythm Pharmaceuticals, Inc.
- Retrophin Inc.
- Palatin Technologies, Inc.
- Obexia AG
- Mallinckrodt Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Melanocortin Receptor 4 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cosyntropin
- 2.2.3 Corticotropin
- 2.2.4 Bremelanotide
- 2.2.5 Others
- 2.3 Melanocortin Receptor 4 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Genito Urinary System
- 2.3.3 Infection Disease
- 2.3.4 Women's Health
- 2.3.5 Metabolic Disorder
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Melanocortin Receptor 4 Breakdown Data by Type
- 3.1 Global Melanocortin Receptor 4 Historic Market Size by Type (2021-2026)
- 3.2 Global Melanocortin Receptor 4 Forecasted Market Size by Type (2027-2032)
4 Melanocortin Receptor 4 Breakdown Data by Application
- 4.1 Global Melanocortin Receptor 4 Historic Market Size by Application (2021-2026)
- 4.2 Global Melanocortin Receptor 4 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Melanocortin Receptor 4 Market Perspective (2021-2032)
- 5.2 Global Melanocortin Receptor 4 Growth Trends by Region
- 5.2.1 Global Melanocortin Receptor 4 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Melanocortin Receptor 4 Historic Market Size by Region (2021-2026)
- 5.2.3 Melanocortin Receptor 4 Forecasted Market Size by Region (2027-2032)
- 5.3 Melanocortin Receptor 4 Market Dynamics
- 5.3.1 Melanocortin Receptor 4 Industry Trends
- 5.3.2 Melanocortin Receptor 4 Market Drivers
- 5.3.3 Melanocortin Receptor 4 Market Challenges
- 5.3.4 Melanocortin Receptor 4 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Melanocortin Receptor 4 Players by Revenue
- 6.1.1 Global Top Melanocortin Receptor 4 Players by Revenue (2021-2026)
- 6.1.2 Global Melanocortin Receptor 4 Revenue Market Share by Players (2021-2026)
- 6.2 Global Melanocortin Receptor 4 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Melanocortin Receptor 4 Head Office and Area Served
- 6.4 Global Melanocortin Receptor 4 Players, Product Type & Application
- 6.5 Global Melanocortin Receptor 4 Manufacturers Established Date
- 6.6 Global Melanocortin Receptor 4 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Melanocortin Receptor 4 Market Size (2021-2032)
- 7.2 North America Melanocortin Receptor 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Melanocortin Receptor 4 Market Size by Country (2021-2026)
- 7.4 North America Melanocortin Receptor 4 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Melanocortin Receptor 4 Market Size (2021-2032)
- 8.2 Europe Melanocortin Receptor 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Melanocortin Receptor 4 Market Size by Country (2021-2026)
- 8.4 Europe Melanocortin Receptor 4 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Melanocortin Receptor 4 Market Size (2021-2032)
- 9.2 Asia-Pacific Melanocortin Receptor 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Melanocortin Receptor 4 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Melanocortin Receptor 4 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Melanocortin Receptor 4 Market Size (2021-2032)
- 10.2 South America Melanocortin Receptor 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Melanocortin Receptor 4 Market Size by Country (2021-2026)
- 10.4 South America Melanocortin Receptor 4 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Melanocortin Receptor 4 Market Size (2021-2032)
- 11.2 Middle East & Africa Melanocortin Receptor 4 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Melanocortin Receptor 4 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Melanocortin Receptor 4 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Pfizer Inc.
- 12.1.1 Pfizer Inc. Company Information
- 12.1.2 Pfizer Inc. Business Overview
- 12.1.3 Pfizer Inc. Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.1.4 Pfizer Inc. Melanocortin Receptor 4 Product Portfolio
- 12.1.5 Pfizer Inc. Recent Developments
- 12.2 AstraZeneca Plc
- 12.2.1 AstraZeneca Plc Company Information
- 12.2.2 AstraZeneca Plc Business Overview
- 12.2.3 AstraZeneca Plc Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.2.4 AstraZeneca Plc Melanocortin Receptor 4 Product Portfolio
- 12.2.5 AstraZeneca Plc Recent Developments
- 12.3 Rhythm Pharmaceuticals, Inc.
- 12.3.1 Rhythm Pharmaceuticals, Inc. Company Information
- 12.3.2 Rhythm Pharmaceuticals, Inc. Business Overview
- 12.3.3 Rhythm Pharmaceuticals, Inc. Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.3.4 Rhythm Pharmaceuticals, Inc. Melanocortin Receptor 4 Product Portfolio
- 12.3.5 Rhythm Pharmaceuticals, Inc. Recent Developments
- 12.4 Retrophin Inc.
- 12.4.1 Retrophin Inc. Company Information
- 12.4.2 Retrophin Inc. Business Overview
- 12.4.3 Retrophin Inc. Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.4.4 Retrophin Inc. Melanocortin Receptor 4 Product Portfolio
- 12.4.5 Retrophin Inc. Recent Developments
- 12.5 Palatin Technologies, Inc.
- 12.5.1 Palatin Technologies, Inc. Company Information
- 12.5.2 Palatin Technologies, Inc. Business Overview
- 12.5.3 Palatin Technologies, Inc. Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.5.4 Palatin Technologies, Inc. Melanocortin Receptor 4 Product Portfolio
- 12.5.5 Palatin Technologies, Inc. Recent Developments
- 12.6 Obexia AG
- 12.6.1 Obexia AG Company Information
- 12.6.2 Obexia AG Business Overview
- 12.6.3 Obexia AG Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.6.4 Obexia AG Melanocortin Receptor 4 Product Portfolio
- 12.6.5 Obexia AG Recent Developments
- 12.7 Mallinckrodt Plc
- 12.7.1 Mallinckrodt Plc Company Information
- 12.7.2 Mallinckrodt Plc Business Overview
- 12.7.3 Mallinckrodt Plc Revenue in Melanocortin Receptor 4 Business (2021-2026)
- 12.7.4 Mallinckrodt Plc Melanocortin Receptor 4 Product Portfolio
- 12.7.5 Mallinckrodt Plc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst